Copyright Reports & Markets. All rights reserved.

Global Eosinophilic Esophagitis Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Eosinophilic Esophagitis Drug Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Budesonide
    • 1.3.3 Fluticasone
    • 1.3.4 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Eosinophilic Esophagitis Drug Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Drugstore
  • 1.5 Global Eosinophilic Esophagitis Drug Market Size & Forecast
    • 1.5.1 Global Eosinophilic Esophagitis Drug Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Eosinophilic Esophagitis Drug Sales Quantity (2020-2031)
    • 1.5.3 Global Eosinophilic Esophagitis Drug Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 AstraZeneca
    • 2.1.1 AstraZeneca Details
    • 2.1.2 AstraZeneca Major Business
    • 2.1.3 AstraZeneca Eosinophilic Esophagitis Drug Product and Services
    • 2.1.4 AstraZeneca Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 AstraZeneca Recent Developments/Updates
  • 2.2 GSK
    • 2.2.1 GSK Details
    • 2.2.2 GSK Major Business
    • 2.2.3 GSK Eosinophilic Esophagitis Drug Product and Services
    • 2.2.4 GSK Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 GSK Recent Developments/Updates
  • 2.3 Bayer
    • 2.3.1 Bayer Details
    • 2.3.2 Bayer Major Business
    • 2.3.3 Bayer Eosinophilic Esophagitis Drug Product and Services
    • 2.3.4 Bayer Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Bayer Recent Developments/Updates
  • 2.4 Adare Pharmaceuticals
    • 2.4.1 Adare Pharmaceuticals Details
    • 2.4.2 Adare Pharmaceuticals Major Business
    • 2.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product and Services
    • 2.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Adare Pharmaceuticals Recent Developments/Updates
  • 2.5 DBV Technologies
    • 2.5.1 DBV Technologies Details
    • 2.5.2 DBV Technologies Major Business
    • 2.5.3 DBV Technologies Eosinophilic Esophagitis Drug Product and Services
    • 2.5.4 DBV Technologies Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 DBV Technologies Recent Developments/Updates
  • 2.6 Dr. Falk Pharma
    • 2.6.1 Dr. Falk Pharma Details
    • 2.6.2 Dr. Falk Pharma Major Business
    • 2.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product and Services
    • 2.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Dr. Falk Pharma Recent Developments/Updates
  • 2.7 Quorum Innovations
    • 2.7.1 Quorum Innovations Details
    • 2.7.2 Quorum Innovations Major Business
    • 2.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Product and Services
    • 2.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Quorum Innovations Recent Developments/Updates
  • 2.8 Takeda
    • 2.8.1 Takeda Details
    • 2.8.2 Takeda Major Business
    • 2.8.3 Takeda Eosinophilic Esophagitis Drug Product and Services
    • 2.8.4 Takeda Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Takeda Recent Developments/Updates
  • 2.9 Calypso
    • 2.9.1 Calypso Details
    • 2.9.2 Calypso Major Business
    • 2.9.3 Calypso Eosinophilic Esophagitis Drug Product and Services
    • 2.9.4 Calypso Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Calypso Recent Developments/Updates
  • 2.10 Celgene
    • 2.10.1 Celgene Details
    • 2.10.2 Celgene Major Business
    • 2.10.3 Celgene Eosinophilic Esophagitis Drug Product and Services
    • 2.10.4 Celgene Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Celgene Recent Developments/Updates
  • 2.11 Regeneron
    • 2.11.1 Regeneron Details
    • 2.11.2 Regeneron Major Business
    • 2.11.3 Regeneron Eosinophilic Esophagitis Drug Product and Services
    • 2.11.4 Regeneron Eosinophilic Esophagitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Regeneron Recent Developments/Updates

3 Competitive Environment: Eosinophilic Esophagitis Drug by Manufacturer

  • 3.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Eosinophilic Esophagitis Drug Revenue by Manufacturer (2020-2025)
  • 3.3 Global Eosinophilic Esophagitis Drug Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Eosinophilic Esophagitis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Eosinophilic Esophagitis Drug Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Eosinophilic Esophagitis Drug Manufacturer Market Share in 2024
  • 3.5 Eosinophilic Esophagitis Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Eosinophilic Esophagitis Drug Market: Region Footprint
    • 3.5.2 Eosinophilic Esophagitis Drug Market: Company Product Type Footprint
    • 3.5.3 Eosinophilic Esophagitis Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Eosinophilic Esophagitis Drug Market Size by Region
    • 4.1.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Eosinophilic Esophagitis Drug Consumption Value by Region (2020-2031)
    • 4.1.3 Global Eosinophilic Esophagitis Drug Average Price by Region (2020-2031)
  • 4.2 North America Eosinophilic Esophagitis Drug Consumption Value (2020-2031)
  • 4.3 Europe Eosinophilic Esophagitis Drug Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Eosinophilic Esophagitis Drug Consumption Value (2020-2031)
  • 4.5 South America Eosinophilic Esophagitis Drug Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Eosinophilic Esophagitis Drug Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 5.2 Global Eosinophilic Esophagitis Drug Consumption Value by Type (2020-2031)
  • 5.3 Global Eosinophilic Esophagitis Drug Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 6.2 Global Eosinophilic Esophagitis Drug Consumption Value by Application (2020-2031)
  • 6.3 Global Eosinophilic Esophagitis Drug Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 7.2 North America Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 7.3 North America Eosinophilic Esophagitis Drug Market Size by Country
    • 7.3.1 North America Eosinophilic Esophagitis Drug Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Eosinophilic Esophagitis Drug Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 8.2 Europe Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 8.3 Europe Eosinophilic Esophagitis Drug Market Size by Country
    • 8.3.1 Europe Eosinophilic Esophagitis Drug Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Eosinophilic Esophagitis Drug Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Eosinophilic Esophagitis Drug Market Size by Region
    • 9.3.1 Asia-Pacific Eosinophilic Esophagitis Drug Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Eosinophilic Esophagitis Drug Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 10.2 South America Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 10.3 South America Eosinophilic Esophagitis Drug Market Size by Country
    • 10.3.1 South America Eosinophilic Esophagitis Drug Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Eosinophilic Esophagitis Drug Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Eosinophilic Esophagitis Drug Market Size by Country
    • 11.3.1 Middle East & Africa Eosinophilic Esophagitis Drug Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Eosinophilic Esophagitis Drug Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Eosinophilic Esophagitis Drug Market Drivers
  • 12.2 Eosinophilic Esophagitis Drug Market Restraints
  • 12.3 Eosinophilic Esophagitis Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Eosinophilic Esophagitis Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Eosinophilic Esophagitis Drug
  • 13.3 Eosinophilic Esophagitis Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Eosinophilic Esophagitis Drug Typical Distributors
  • 14.3 Eosinophilic Esophagitis Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Eosinophilic Esophagitis Drug market size was valued at US$ 149 million in 2024 and is forecast to a readjusted size of USD 213 million by 2031 with a CAGR of 5.4% during review period.
    Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

    Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

    This report studies the eosinophilic esophagitis drug market.
    AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.
    North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.
    This report is a detailed and comprehensive analysis for global Eosinophilic Esophagitis Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Eosinophilic Esophagitis Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Eosinophilic Esophagitis Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Eosinophilic Esophagitis Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Eosinophilic Esophagitis Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Eosinophilic Esophagitis Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Eosinophilic Esophagitis Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Takeda, Calypso, Celgene, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Eosinophilic Esophagitis Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Budesonide
    Fluticasone
    Others
    Market segment by Application
    Hospitals
    Clinics
    Drugstore
    Major players covered
    AstraZeneca
    GSK
    Bayer
    Adare Pharmaceuticals
    DBV Technologies
    Dr. Falk Pharma
    Quorum Innovations
    Takeda
    Calypso
    Celgene
    Regeneron
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Eosinophilic Esophagitis Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Eosinophilic Esophagitis Drug, with price, sales quantity, revenue, and global market share of Eosinophilic Esophagitis Drug from 2020 to 2025.
    Chapter 3, the Eosinophilic Esophagitis Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Eosinophilic Esophagitis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Eosinophilic Esophagitis Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Eosinophilic Esophagitis Drug.
    Chapter 14 and 15, to describe Eosinophilic Esophagitis Drug sales channel, distributors, customers, research findings and conclusion.

    Buy now